Login / Signup

Novel Acylguanidine-Based Inhibitor of HIV-1.

Philip MwimanziIan TietjenScott C MillerAniqa ShahidKyle CobarrubiasNatalie N KinlochBemuluyigza BarakiJonathan RichardAndrés FinziDavid FedidaZabrina L BrummeMark A Brockman
Published in: Journal of virology (2016)
New inhibitors of HIV-1 replication may be useful as therapeutics to counteract drug resistance and as reagents to perform more detailed studies of viral pathogenesis. SM111 is a small molecule that blocks the replication of wild-type and drug-resistant HIV-1 strains by impairing viral release and substantially reducing virion infectivity, most likely through its ability to prevent Env expression at the infected cell surface. Partial resistance to SM111 is mediated by mutations in Vpu and/or Env, suggesting that the compound affects host/viral protein interactions that are important during viral egress. Further characterization of SM111 and similar compounds may allow more detailed pharmacological studies of HIV-1 egress and provide opportunities to develop new treatments for HIV-1.
Keyphrases